跳至主要内容
临床试验/NCT06706973
NCT06706973招募中不适用

Profiling and Targeting Epigenetic Marks to Improve Diagnosis and Therapeutic Approaches in Head and Neck Cancer

European Institute of Oncology1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2024年3月6日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
60
试验地点
1
主要终点
PROFILING AND TARGETING EPIGENETIC MARKS TO IMPROVE DIAGNOSIS AND THERAPEUTIC APPROACHES IN HEAD AND NECK CANCER

研究概览

简要总结

Investigators have recently shown that epigenetic remodelling enzymes, such as HDAC inhibitors, are feasible drugs in HNC (8, 9). Preliminary data are indicating some deregulated epigenetics marks suggesting the corresponding histone modifiers as possible targets for the treatment of HNC, providing an attractive and feasible option to build upon. Our overarching hypothesis is that unique histone marks distinguish HPV+ and HPV- HNC and that specific histone modifiers are novel mediators of HNC tumorigenesis in an HPV specific manner

详细描述

Head and neck cancer (HNC) is a highly heterogeneous disease, involving diverse anatomical sites including oral cavity, larynx and oropharynx. HNC risk factors include tobacco smoking and alcohol consumption and, especially for the subtype of oropharyngeal cancers (OPC), human papillomavirus (HPV) infection

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age: Adults aged ≥ 18 years diagnosed with HNC
  • Sex: Both male and female
  • Human papilloma virus (HPV) test: Both positive and negative.
  • Tumor: primary tumors, treatment naïve, squamous cell carcinoma
  • Cancer stage: I-IV
  • Anatomic location: oral cavity, larynx, oropharynx
  • Tumor fragments not required for diagnostics

排除标准

  • Previous radiotherapy, chemotherapy or immunotherapy for HNC
  • Unable to provide written informed consent

结局指标

主要结局

PROFILING AND TARGETING EPIGENETIC MARKS TO IMPROVE DIAGNOSIS AND THERAPEUTIC APPROACHES IN HEAD AND NECK CANCER

时间窗: 2 years

define and fully characterize histone Post-Translational Modifications (hPTMs) and differentially expressed chromatin modifiers in HPV+ vs HPV- HNC through cutting-edge methodologies

次要结局

未报告次要终点

研究者

发起方
European Institute of Oncology
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Profiling and Targeting Epigenetic Marks to Improve... | 临床试验